Poor
Mostly Aligned
Patient Risk:
Low
Summary
Core indication and mechanism statements are supported by the label, but the majority of other factual claims (approval timing, manufacturer, patents, market context, comparative therapies, cost, and patient programs) are not addressed by the label, or are not present in the provided label excerpts. Overall alignment is limited.
Category Scores
Accurate Statements
Qulipta (atogepant) is indicated for the preventive treatment of migraine in adults.
Indications and Usage (1)
Qulipta belongs to the CGRP receptor antagonist class.
Mechanism of Action (12.1)
Qulipta works by blocking CGRP and helps prevent migraine attacks.
Mechanism of Action (12.1); Indications and Usage (1)
Unsupported Statements
Qulipta was approved by the FDA in September 2021.
Not present in the supplied label excerpts.
This means it has been available on the market for approximately two years and seven months as of May 2024.
Not present in the supplied label excerpts.
The primary patent covering Qulipta, U.S. Patent No. 10,500,401, is scheduled to expire in June 2037.
Not present in the supplied label excerpts.
Qulipta is manufactured by AbbVie Inc.
Not present in the supplied label excerpts.
AbbVie acquired Allergan, the original developer of Qulipta, in 2020.
Not present in the supplied label excerpts.
Qulipta is one of several CGRP-targeted therapies available for migraine prevention.
Not present in the label excerpts.
Other medications in this class include oral gepants like Ubrelvy (ubrogepant) and Nurtec ODT (rimegepant).
Not present in the label excerpts.
Other medications in this class include injectable monoclonal antibodies such as Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), and Vyepti (eptinezumab).
Not present in the label excerpts.
The cost of Qulipta can vary depending on insurance coverage and pharmacy.
Not present in the label excerpts.
AbbVie offers patient assistance programs that may help eligible individuals reduce their out-of-pocket costs.
Not present in the label excerpts.
Contradictions
Important Omissions
Contraindications
Importance:
High
Boxed Warnings (if any) and Warnings and Precautions
Importance:
High
Dosage and Administration details (starting dose, titration, maximum daily dose, hepatic considerations)
Importance:
High
Pregnancy risk data (8.1)
Importance:
High
Pediatric Use (8.4)
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Claims focus on mechanism and indication with no new safety signals presented.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several non-label claims are included; enhance alignment by restricting content to on-label information and add label-derived dosing and safety details.
Suggested Improvement
Limit claims to those supported by the label (indication, mechanism, and key efficacy endpoints). Include explicit dosage and administration guidance, contraindications, boxed warnings (if any), monitoring recommendations, and safety data from the label. Consider citing the relevant sections (e.g., 1, 2, 6, 8.1, 8.4, 12.1) as applicable.